Topic:

M&A

Latest Headlines

Latest Headlines

Hours after receiving new bid, Perrigo tells Mylan to take a hike

Just a couple hours after Mylan sweetened its original bid for Ireland's Perrigo to $31 billion-plus, Perrigo nixed the new offer. Why? The way the target sees it, it isn't quite so sweet.

In an affront to Teva, Mylan hikes Perrigo offer past $31B

Mylan sent a message to Teva that it wasn't interested in becoming bait even before the Israeli drugmaker made its $40 billion bid earlier this week. Now, it's repeating that message loud and clear--and it's doing so with a sweetened offer for Irish target Perrigo.

Sartorius snags U.K. CRO BioOutsource with an eye on biosimilars

Biopharma production specialist Sartorius Stedim Biotech has acquired BioOutsource, a U.K. CRO focused on the growing demand for knockoffs of top-selling biologics.

Gilead should buy Vertex, analyst suggests--and the time is now

While pharma's been riding its deal wave, Gilead's been off on its own, coasting on new revenue from blockbuster hep C launches Sovaldi and Harvoni. But one analysts thinks the time is ripe for it to get in on the M&A action--and he's tabbed Vertex as a prime target.

Teva wants Mylan wants Perrigo, and the pundits go mad with opinions

Rumors of a Teva-Mylan merger have swirled for weeks, and now that Teva's bid has actually arrived, the talk is heating up even more. Everyone has an opinion--Mylan and Teva included--and those opinions are all over the map. Strategic or not? Legally possible or not? At what price might Mylan be willing to talk? And could Mylan persuade the reluctant Perrigo to take its (defensive) $29 billion offer? 

Deep discounts allow Remicade biosimilar to grab 50% of Norway's market

Conventional thinking is that the complexity of biosimilars will keep their discounts to just 20% to 30% of the branded price. Think again. In Norway a biosimilar of Merck's arthritis blockbuster Remicade is going for a discount of nearly 70%, upsetting conventional wisdom and competitors.

Perrigo spurned Mylan's $29B offer, but would a bigger one do?

Bad news for Mylan if it wants to avoid a $40 billion takeover by generics rival Teva: Its own acquisition prospect, Ireland's Perrigo, isn't interested in getting together.

Think the pharma M&A party will start winding down? Think again

Investors like pharma M&A. Drugmakers have money--or access to it. Ergo, look for the dealmaking frenzy to continue, a Morgan Stanley equity strategist says. The pharma industry accounted for 45% of U.S. M&A so far this quarter, Bloomberg reports, and at least 20% of the value of all offers over the last two quarters.

Boosted by Opsumit, one-time target Actelion is ready to make its own deals

Actelion hasn't been too keen on becoming an M&A target lately. But if it's the one in the driver's seat? Bring on the deals, CFO André Muller says.

Does a $45B Vertex buyout make sense for Gilead? Porges says heck yes

Bernstein's Geoffrey Porges has run the numbers on what a Gilead takeover of Vertex would look like. And he loves what he sees.